Status:

TERMINATED

Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy

Lead Sponsor:

Joslin Diabetes Center

Collaborating Sponsors:

Novo Nordisk A/S

Conditions:

Type 1 Diabetes Mellitus

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

The purpose of this study is to determine: 1. whether there is a difference between insulin aspart and insulin lispro in continuous insulin pump therapy 2. whether duration of the insulin infusion se...

Detailed Description

Insulin instability in pump infusion systems can result in unexplained hyperglycemia in patients on continuous subcutaneous insulin infusion (CSII) therapy. We have noted that some pump patients devel...

Eligibility Criteria

Inclusion

  • Type 1 diabetes treated with CSII at least 3 months.
  • Males and females, \> 18 years but \< 75 years old.
  • Hemoglobin A1c ≤ 8.0 % at measurement taken at week 0 (screening visit).
  • Duration of diabetes ≥ 12 months.
  • Willingness to perform self-blood glucose monitoring several times/day.

Exclusion

  • Previous insulin precipitation in pump infusion catheters.
  • Daily insulin requirements \> 25% of pump reservoir capacity. (This would preclude the subject from using the pump infusion system for more than 3 days).
  • Use of an insulin pump that does not have a downloadable record of basal and bolus doses.
  • Known or suspected allergy to trial products.
  • Pregnancy, breast-feeding, intention to become pregnant or inadequate contraception measures.
  • Known or suspected alcohol or drug abuse.
  • Impaired renal function with creatinine ≥ 1.7 mg/dl.
  • Pronounced catheter site scarring.
  • Chronic use of drugs that may influence glycemic control (e.g. steroids).
  • Any other significant concomitant disease that would interfere with participation in and completion of the trial.

Key Trial Info

Start Date :

February 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2008

Estimated Enrollment :

4 Patients enrolled

Trial Details

Trial ID

NCT00428207

Start Date

February 1 2007

End Date

August 1 2008

Last Update

May 30 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Joslin Diabetes Center

Boston, Massachusetts, United States, 02215